Physician profile
Daniel Lebovic
NPI 1568645950
$51,308.87
in general payments reported to CMS, 2019-2025
71 companies · $11K in 2025
The $11K reported for 2025 was more than what 89% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $4,584 · 2021: $6,710 · 2022: $2,105 · 2023: $2,361 · 2024: $2,306 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,238 · Food and Beverage: $7,134 · Education: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,237.83 |
| Food and Beverage | $7,134.06 |
| Education | $156.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $21,189.99 | 2019-2023 | Xarelto |
| Pfizer INC. | $9,835.91 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $8,479.41 | 2019-2025 | Lynozyfic, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $1,957.93 | 2019-2025 | Opdivo, Opdualag, Augtyro |
| Novartis Pharmaceuticals Corporation | $1,058.89 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $879.49 | 2019-2025 | Imfinzi, Enhertu, Calquence |
| Janssen Biotech, INC. | $598.22 | 2019-2025 | Erleada, Darzalex, Tecvayli |
| Daiichi Sankyo INC. | $523.05 | 2020-2025 | Enhertu, Datroway, Injectafer |
| Abbvie INC. | $497.80 | 2019-2025 | |
| Genentech USA, INC. | $473.85 | 2019-2025 | Venclexta, Phesgo, Polivy |
| Astellas Pharma US INC | $403.87 | 2019-2025 | Xtandi, Vyloy, Xospata |
| Incyte Corporation | $327.95 | 2019-2025 | Pemazyre, Jakafi, Monjuvi |
| Eisai INC. | $310.06 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $294.47 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $250.46 | 2019-2025 |
Show all 71 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $248.81 | 2019-2023 | Kyprolis, Blincyto, Nplate |
| Karyopharm Therapeutics INC. | $236.26 | 2023-2025 | Xpovio |
| Seagen INC. | $214.34 | 2019-2023 | Adcetris, Tukysa, Padcev |
| Gilead Sciences, INC. | $207.51 | 2019-2025 | Trodelvy |
| Genmab U.S., INC. | $197.74 | 2023-2025 | Tivdak, Epkinly |
| Stemline Therapeutics INC. | $181.77 | 2023-2025 | Orserdu |
| Genzyme Corporation | $178.32 | 2019-2025 | |
| Kite Pharma, INC. | $175.53 | 2022-2025 | Yescarta |
| Lilly USA, LLC | $161.94 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Puma Biotechnology, INC. | $149.58 | 2021-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $149.20 | 2019-2023 | Imbruvica, Epkinly |
| Celgene Corporation | $133.53 | 2023-2025 | Reblozyl |
| Array Biopharma INC | $124.19 | 2019-2024 | Braftovi, Lorbrena, Mektovi |
| Myovant Sciences INC. | $110.13 | 2021-2022 | |
| Acrotech Biopharma INC. | $97.35 | 2021-2024 | Beleodaq |
| Mirati Therapeutics, INC. | $90.61 | 2023-2024 | Krazati |
| Ipsen Biopharmaceuticals, INC | $87.63 | 2023-2025 | Somatuline Depot, Onivyde |
| Pharmacosmos Therapeutics INC. | $82.14 | 2023-2024 | Monoferric |
| Glaxosmithkline, LLC. | $78.43 | 2022-2025 | Ojjaara, Shingrix |
| Tersera Therapeutics LLC | $76.69 | 2023-2024 | Zoladex |
| Takeda Pharmaceuticals U.S.A., INC. | $74.06 | 2019-2025 | Ninlaro, Alunbrig |
| Mylan Institutional INC. | $67.49 | 2022-2023 | Ogivri, Fulphila |
| Apellis Pharmaceuticals, INC. | $67.22 | 2023-2024 | Empaveli |
| Morphosys, US INC. | $66.49 | 2021-2024 | Monjuvi |
| Blueprint Medicines Corporation | $59.31 | 2022-2023 | Ayvakit |
| Emd Serono, INC. | $58.41 | 2019-2025 | |
| Foundation Medicine, INC. | $54.94 | 2019-2023 | |
| Beone Medicines USA, INC. | $51.44 | 2025 | Brukinsa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.10 | 2021-2025 | |
| G1 Therapeutics, INC. | $43.28 | 2023 | Cosela |
| Rigel Pharmaceuticals, INC. | $42.41 | 2022-2023 | Rezlidhia, Tavalisse |
| Sun Pharmaceutical Industries INC. | $41.84 | 2022-2023 | Yonsa, Odomzo |
| Jazz Pharmaceuticals INC. | $41.14 | 2019-2021 | |
| Myriad Genetic Laboratories, INC. | $40.04 | 2024 | Myrisk |
| Aveo Pharmaceuticals, INC. | $38.46 | 2024 | |
| Adc Therapeutics America, INC. | $34.16 | 2024-2025 | |
| Organon LLC | $32.22 | 2023 | Ontruzant |
| Dova Pharmaceuticals | $30.81 | 2019-2020 | |
| Immunogen, INC. | $28.80 | 2023 | Elahere |
| Taiho Oncology, INC. | $26.56 | 2019-2022 | |
| Pharming Healthcare, INC. | $26.00 | 2022 | |
| Sobi, INC | $24.03 | 2025 | |
| Beigene USA, INC. | $23.57 | 2024 | Brukinsa, Tevimbra |
| Pharmaessentia USA Corporation | $21.89 | 2023 | Besremi |
| Exelixis INC. | $21.71 | 2025 | Cabometyx |
| Csl Behring | $21.31 | 2024 | Hizentra |
| Helsinn Therapeutics (U.S.), INC. | $19.08 | 2019 | |
| Heron Therapeutics, INC. | $18.96 | 2022 | |
| Recordati_rare_diseases_inc. | $17.79 | 2024 | Sylvant |
| Agios Pharmaceuticals, INC. | $15.79 | 2022 | |
| Servier Pharmaceuticals LLC | $15.71 | 2024 | |
| Azurity Pharmaceuticals, INC. | $15.33 | 2025 | Danziten |
| Spectrum Pharmaceuticals INC. | $15.18 | 2019 | |
| Secura Bio, INC. | $15.02 | 2024 | Copiktra |
| Deciphera Pharmaceuticals INC. | $14.94 | 2025 | Qinlock, Tgct |
| Alexion Pharmaceuticals, INC. | $14.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Lebovic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.